Legalize / Ireland / Statutory Instrument

S.I. No. 582/2024 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024

Type Statutory Instrument

Publication 2024-11-01

Last updated 2026-09-08

State Repealed superseded text

Text As published

Source Irish Statute Book

articles 3

This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.

1 amending act · 2026-09-08, S.I. No. 457/2026 - Medicinal Products (Prescription and Control of Supply) (Amendment) R…

Reform history JSON API

Notice of the making of this Statutory Instrument was published in

“Iris Oifigiúil” of 1st November, 2024.

I, STEPHEN DONNELLY, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations:

1.

(1) These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024.

(2) The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2024” includes these Regulations.

2.

These Regulations shall come into operation on 31^st October 2024.

3.

In these Regulations –

“Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 );

“Regulations of 2024” means the Medicinal Products (Prescription and Control of Supply) (No. 4) Regulations 2024 ( S.I. No. 458 of 2024 ).

The Eighth Schedule (as amended by Regulation 7 of the 2024 Regulations) to the Principal Regulations is amended by inserting the following entry:

“

Medicinal product Form and presentation of the product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration Place of administration

Column 1 Column 2 Column 3 Column 4 Column 5 Column 6

Comirnaty KP.2 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.

Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.

Comirnaty KP.23 micrograms/dose concentrate for dispersion COVID-19 mRNA Vaccine Concentrate for dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.

Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health. Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.

”.


Medicinal product	Form and presentation of the product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration	Place of administration
Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
Comirnaty KP.2 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine	Dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.	Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.
Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine	Dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.	Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.
Comirnaty KP.23 micrograms/dose concentrate for dispersion COVID-19 mRNA Vaccine	Concentrate for dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.	Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.
Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)	Dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.	Any suitable and appropriate place, having regard to public convenience and the need to protect the health and safety of the public and safely administer the product.

The Twelfth Schedule (as amended by Regulation 8 of the 2024 Regulations) to the Principal Regulations is amended by inserting the following entry:

“

Medicinal product Form and presentation of product administered Route of administration Indication for which the medicinal product may be administered Dosage and conditions of administration

Column 1 Column 2 Column 3 Column 4 Column 5

Comirnaty KP.2 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.

Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.

Comirnaty KP.2 3 micrograms/dose concentrate for dispersion COVID-19 mRNA Vaccine Concentrate for dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.

Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) Dispersion for injection Intramuscular injection Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.

”.


Medicinal product	Form and presentation of product administered	Route of administration	Indication for which the medicinal product may be administered	Dosage and conditions of administration
Column 1	Column 2	Column 3	Column 4	Column 5
Comirnaty KP.2 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine	Dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.
Comirnaty KP.2 10 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine	Dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.
Comirnaty KP.2 3 micrograms/dose concentrate for dispersion COVID-19 mRNA Vaccine	Concentrate for dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.
Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)	Dispersion for injection	Intramuscular injection	Indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older	In accordance with the summary of product characteristics and the relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health.

GIVEN under my Official Seal,

30 October, 2024.

STEPHEN DONNELLY,

Minister for Health.

EXPLANATORY NOTE

(This note is not part of the Instrument and does not purport to be a legal

interpretation.)

These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations 2003.

The purpose of these Regulations is to update the schedules of medicinal products which may be supplied and administered pursuant to Regulation 4B and Regulation 4F of the Medicinal Products (Prescription and Control of Supply) Regulations 2003.

These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2024.

This document does not substitute the official text published in the Irish Statute Book. We accept no responsibility for any inaccuracies arising from the transcription of the original into this format.

This text is published under Irish Statute Book's own terms of reuse, not a Legalize or public-domain licence. Irish Statute Book
CC-BY 4.0 (Oireachtas Open Data PSI Licence)
Contains Irish Public Sector Information licensed under the Oireachtas (Houses of the Oireachtas) Open Data PSI Licence / Creative Commons Attribution 4.0 International, sourced from https://www.irishstatutebook.ie.